Subscribe
shutterstock_1569359980_sundry-photography
shutterstock_1569359980_Sundry Photography
10 January 2023AmericasMuireann Bolger

Gilead avoids $1.2bn patent clash at SCOTUS

Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Big Pharma
Gilead defeats immunity bid in hepatitis C patent case
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Big Pharma
Gilead defeats US govt in billion-dollar HIV drug patent suit
11 May 2023   Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Big Pharma
Gilead defeats immunity bid in hepatitis C patent case
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Big Pharma
Gilead defeats US govt in billion-dollar HIV drug patent suit
11 May 2023   Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

More on this story

Big Pharma
Trial set for Gilead HIV antitrust claims case
23 February 2023   Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.
Big Pharma
Gilead defeats immunity bid in hepatitis C patent case
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Big Pharma
Gilead defeats US govt in billion-dollar HIV drug patent suit
11 May 2023   Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?